Please provide your email address to receive an email when new articles are posted on . Any bleeding event regardless of severity can adversely impact a patient. Factor XI and XIa inhibitors in ...
Hosted on MSN
Anti-clotting drug significantly reduces bleeding events in patients with atrial fibrillation, clinical trial shows
The team found that the 150 mg dose of abelacimab reduced bleeding that required hospitalization or medical attention by 62%, compared with rivaroxaban. The 90 mg dose of abelacimab reduced the same ...
Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback